数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
David T. Feinberg President, Chief Executive Officer and Director 59 2049.91万美元 未持股 2022-04-11
Elder Granger Director 68 33.35万美元 未持股 2022-04-11
Julie L. Gerberding Director 66 32.85万美元 0.81 2022-04-11
John J. Greisch Director 66 35.85万美元 1.53 2022-04-11
Melinda J. Mount Director 62 34.54万美元 0.64 2022-04-11
William D. Zollars Chairman of the Board 74 43.11万美元 2.29 2022-04-11
George A. Riedel Director 64 34.10万美元 0.47 2022-04-11
Mitchell E. Daniels, Jr. Director 73 34.35万美元 3.06 2022-04-11
R. Halsey Wise Director 57 34.85万美元 1.37 2022-04-11

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
David T. Feinberg President, Chief Executive Officer and Director 59 2049.91万美元 未持股 2022-04-11
Tracy L. Platt Executive Vice President and Chief Human Resources Officer 48 366.43万美元 未持股 2022-04-11
Travis S. Dalton Executive Vice President, Chief Client,Services Officer and President, Cerner Government Services 51 581.85万美元 未持股 2022-04-11
Daniel P. Devers Executive Vice President, Chief Legal Officer and Secretary 49 未披露 未持股 2022-04-11
Jerome Labat Executive Vice President and Chief Technology Officer 56 636.13万美元 未持股 2022-04-11
Nasim Afsarmanesh Executive Vice President and Chief Health Officer 44 未披露 未持股 2022-04-11
Mark J. Erceg Executive Vice President and Chief Financial Officer 52 968.06万美元 未持股 2022-04-11

董事简历

中英对照 |  中文 |  英文
David T. Feinberg

David T. Feinberg,2010年3月起担任本公司董事。他自2011年7月起,担任UCLA Health System的总裁;2007年7月起,担任UCLA Hospital System的首席执行官,及协理副校长。担任上述职务之前,他是Resnick Neuropsychiatric Hospital NPH at UCLA的医疗总监。他是委员会认证的,儿童和青少年精神病学、成人精神病学和成瘾精神病方面的专业人士。他是 David Geffen School of Medicine at UCLA的临床精神病学教授。他现为Douglas Emmett, Inc.的董事,这是纽交所上市的房地产投资信托基金。1984年,他以优异的成绩毕业于University of California, Berkeley的经济学专业;1989年,以优等生毕业于University of Health Sciences/The Chicago Medical School。2002年,他从获得了Pepperdine University工商管理硕士学位。他当选为董事,是由于他对于医疗行业的丰富知识,以及管理大型国际知名医院系统的经验。


David T. Feinberg,was initially elected to the Board in March 2022. Dr. Feinberg is Chairman of Oracle Health, where he is committed to making healthcare more accessible, affordable, and equitable. His work advances thought leadership and strategy related to unleashing the healing power of data through an open and connected healthcare ecosystem. Previously, Dr. Feinberg served as President and Chief Executive Officer and member of the Board of Directors of Cerner Corporation (Cerner), which is now Oracle Health. In that role Dr. Feinberg focused on delivering tools and technology to help caregivers optimize the health of their patients and communities.Dr. Feinberg joined Cerner from Google, where he held the position of Vice President of Google Health since 2019 and led Google's worldwide health efforts, bringing together groups from across Google and Alphabet that Humana Inc. ed artificial intelligence, product expertise and hardware to tackle some of healthcare's biggest challenges, and was responsible for organizing and innovating Google's various healthcare initiatives. Prior to Google, he served as President and CEO of Geisinger Health where he led an operational turnaround, and pushed the Humana Inc. e of new platforms and tools, including an IT system called a Unified Data Architecture that allowed the company to integrate big data into existing data analytics and management systems. During his Geisinger tenure, Dr. Feinberg also introduced programs and services to put a greater focus on precision medicine and better patient care. Prior to Geisinger, Dr. Feinberg worked at UCLA for more than 20 years and served in a number of leadership roles, including President, CEO and Associate Vice Chancellor of UCLA Health Sciences, Vice Chancellor and CEO for the UCLA Hospital System, and CEO of UCLA's Ronald Reagan Medical Center.Dr. Feinberg earned his undergraduate degree at the University of California, Berkeley. He graduated with distinction from the University of Health Sciences/Chicago Medical School. He completed an internship in pediatrics at Loyola University Medical Center, and residency and fellowship training in psychiatry, addiction psychiatry, and child and adolescent psychiatry at the UCLA School of Medicine. He earned a Master of Business Administration from Pepperdine University. Dr. Feinberg is a member of the Alpha Omega Alpha Medical Honor Society, a Distinguished Fellow of American Psychiatric Association and received the Cancro Academic Leadership Award from the American Academy of Child & Adolescent Psychiatry. Dr. Feinberg also serves on the Board of Directors of Douglas Emmett Inc.
David T. Feinberg,2010年3月起担任本公司董事。他自2011年7月起,担任UCLA Health System的总裁;2007年7月起,担任UCLA Hospital System的首席执行官,及协理副校长。担任上述职务之前,他是Resnick Neuropsychiatric Hospital NPH at UCLA的医疗总监。他是委员会认证的,儿童和青少年精神病学、成人精神病学和成瘾精神病方面的专业人士。他是 David Geffen School of Medicine at UCLA的临床精神病学教授。他现为Douglas Emmett, Inc.的董事,这是纽交所上市的房地产投资信托基金。1984年,他以优异的成绩毕业于University of California, Berkeley的经济学专业;1989年,以优等生毕业于University of Health Sciences/The Chicago Medical School。2002年,他从获得了Pepperdine University工商管理硕士学位。他当选为董事,是由于他对于医疗行业的丰富知识,以及管理大型国际知名医院系统的经验。
David T. Feinberg,was initially elected to the Board in March 2022. Dr. Feinberg is Chairman of Oracle Health, where he is committed to making healthcare more accessible, affordable, and equitable. His work advances thought leadership and strategy related to unleashing the healing power of data through an open and connected healthcare ecosystem. Previously, Dr. Feinberg served as President and Chief Executive Officer and member of the Board of Directors of Cerner Corporation (Cerner), which is now Oracle Health. In that role Dr. Feinberg focused on delivering tools and technology to help caregivers optimize the health of their patients and communities.Dr. Feinberg joined Cerner from Google, where he held the position of Vice President of Google Health since 2019 and led Google's worldwide health efforts, bringing together groups from across Google and Alphabet that Humana Inc. ed artificial intelligence, product expertise and hardware to tackle some of healthcare's biggest challenges, and was responsible for organizing and innovating Google's various healthcare initiatives. Prior to Google, he served as President and CEO of Geisinger Health where he led an operational turnaround, and pushed the Humana Inc. e of new platforms and tools, including an IT system called a Unified Data Architecture that allowed the company to integrate big data into existing data analytics and management systems. During his Geisinger tenure, Dr. Feinberg also introduced programs and services to put a greater focus on precision medicine and better patient care. Prior to Geisinger, Dr. Feinberg worked at UCLA for more than 20 years and served in a number of leadership roles, including President, CEO and Associate Vice Chancellor of UCLA Health Sciences, Vice Chancellor and CEO for the UCLA Hospital System, and CEO of UCLA's Ronald Reagan Medical Center.Dr. Feinberg earned his undergraduate degree at the University of California, Berkeley. He graduated with distinction from the University of Health Sciences/Chicago Medical School. He completed an internship in pediatrics at Loyola University Medical Center, and residency and fellowship training in psychiatry, addiction psychiatry, and child and adolescent psychiatry at the UCLA School of Medicine. He earned a Master of Business Administration from Pepperdine University. Dr. Feinberg is a member of the Alpha Omega Alpha Medical Honor Society, a Distinguished Fellow of American Psychiatric Association and received the Cancro Academic Leadership Award from the American Academy of Child & Adolescent Psychiatry. Dr. Feinberg also serves on the Board of Directors of Douglas Emmett Inc.
Elder Granger

Elder Granger于2014年11月当选为董事会成员。Granger博士是退休的美国陆军少将,以及5Ps LLC的总裁兼首席执行官。 Granger博士此前从2011年10月起担任DLH的战略顾问委员会顾问,直至当选为董事会成员。Granger博士在美国陆军服役超过35年,并于2005年至2009年担任华盛顿特区负责国防部长(卫生事务)办公室TRICARE管理活动的副主任和项目执行官。他曾担任助理国防部长(卫生事务)的国防部健康计划,政策和绩效的首席顾问。监督了军队卫生系统内国防部管理式医疗计划的收购,运营和整合。加盟TRICARE管理活动,Granger博士领导的美国和最大的跨国战场卫生系统,同时服务于指挥官,特遣部队第44医务司令部和司令部医生为多国部队伊拉克。目前,Granger博士是The 5Ps,LLC的总裁兼首席执行官,该医疗保健,教育和领导咨询公司是在他从美国军队退休后成立的。格兰杰博士获得了阿肯色州立大学的学士学位,并获得了阿肯色大学医学院的医学学位。从阿肯色大学医学院毕业后,他被授予Henry Kaiser医疗卓越和领导力医疗奖学金。 Granger博士获得了美国医师管理学院,美国医学质量委员会,美国内科医学委员会,肿瘤内科,血液学委员会的认证,并拥有多项医学证书。公司董事的全国协会,研究员,Granger目前担任Express Scripts的控股有限公司的董事会(成员 - 遵约委员会),并还额外privately-的董事会的现任和前任顾问或成员举办公司。Granger博士还是罗莎琳德富兰克林医学和科学大学董事会成员以及阿肯色大学医学院访客委员会成员。


Elder Granger,was elected to Dlh Holdings Corp. Board of Directors in November 2014. Dr. Granger is a U.S. Army Major General (retired) and the President and Chief Executive Officer of The 5Ps LLC. Dr. Granger previously served as an advisor to DLH on its strategic advisory board from October 2011 until his election to the Board. Dr. Granger served in the U.S. Army for over 35 years and was the Deputy Director and Program Executive Officer of the TRICARE Management Activity, Office of the Assistant Secretary of Defense (Health Affairs) in Washington, D.C. from 2005 to 2009. In this role he served as the principal advisor to the Assistant Secretary of Defense (Health Affairs) on DoD health plan, policy and performance. He oversaw the acquisition, operation and integration of DoD's managed care program within the Military Health System. Prior to joining TRICARE Management Activity, Dr. Granger led the largest U.S. and multi-national battlefield health system in Dlh Holdings Corp. recent history while serving as Commander, Task Force 44th Medical Command and Command Surgeon for the Multinational Corps Iraq. Presently, Dr. Granger is the President and CEO of The 5Ps, LLC, a healthcare, education, and leadership consultancy he founded following his retirement from the U.S. Army. Dr. Granger received a B.S. Degree from Arkansas State University and earned his medical degree from University of Arkansas School of Medicine. Upon graduation from the University of Arkansas School of Medicine, he was awarded the Henry Kaiser Medical Fellowship for Medical Excellence and Leadership. Dr. Granger is board certified by the American College of Physician Executives, American Board of Medical Quality, American Board of Internal Medicine, Medical Oncology, Hematology, and holds numerous medical certifications. Additionally, Dr. Granger has earned the CERT Certificate in Cybersecurity Oversight from Carnegie Mellon University. A National Association of Corporate Director, Certified Director and Fellow, Dr. Granger currently serves on the board of directors of Cigna Corp., since December 2018 (chair – Compliance Committee and member – Corporate Governance Committee), and Better Therapeutics, Inc. since 2021 (member – Audit Committee). He served on the board of Express Scripts Holding from 2015 until its merger with Cigna Corp. and served on the board of Cerner Corp. from November 2020 to June 2022 (member – Audit Committee and Nominating, Governance and Public Policy Committee). Dr. Granger is also a current and former advisor or member of the board of directors of additional privately-held companies and also serves on the Board of Visitors of the University of Arkansas School of Medicine.
Elder Granger于2014年11月当选为董事会成员。Granger博士是退休的美国陆军少将,以及5Ps LLC的总裁兼首席执行官。 Granger博士此前从2011年10月起担任DLH的战略顾问委员会顾问,直至当选为董事会成员。Granger博士在美国陆军服役超过35年,并于2005年至2009年担任华盛顿特区负责国防部长(卫生事务)办公室TRICARE管理活动的副主任和项目执行官。他曾担任助理国防部长(卫生事务)的国防部健康计划,政策和绩效的首席顾问。监督了军队卫生系统内国防部管理式医疗计划的收购,运营和整合。加盟TRICARE管理活动,Granger博士领导的美国和最大的跨国战场卫生系统,同时服务于指挥官,特遣部队第44医务司令部和司令部医生为多国部队伊拉克。目前,Granger博士是The 5Ps,LLC的总裁兼首席执行官,该医疗保健,教育和领导咨询公司是在他从美国军队退休后成立的。格兰杰博士获得了阿肯色州立大学的学士学位,并获得了阿肯色大学医学院的医学学位。从阿肯色大学医学院毕业后,他被授予Henry Kaiser医疗卓越和领导力医疗奖学金。 Granger博士获得了美国医师管理学院,美国医学质量委员会,美国内科医学委员会,肿瘤内科,血液学委员会的认证,并拥有多项医学证书。公司董事的全国协会,研究员,Granger目前担任Express Scripts的控股有限公司的董事会(成员 - 遵约委员会),并还额外privately-的董事会的现任和前任顾问或成员举办公司。Granger博士还是罗莎琳德富兰克林医学和科学大学董事会成员以及阿肯色大学医学院访客委员会成员。
Elder Granger,was elected to Dlh Holdings Corp. Board of Directors in November 2014. Dr. Granger is a U.S. Army Major General (retired) and the President and Chief Executive Officer of The 5Ps LLC. Dr. Granger previously served as an advisor to DLH on its strategic advisory board from October 2011 until his election to the Board. Dr. Granger served in the U.S. Army for over 35 years and was the Deputy Director and Program Executive Officer of the TRICARE Management Activity, Office of the Assistant Secretary of Defense (Health Affairs) in Washington, D.C. from 2005 to 2009. In this role he served as the principal advisor to the Assistant Secretary of Defense (Health Affairs) on DoD health plan, policy and performance. He oversaw the acquisition, operation and integration of DoD's managed care program within the Military Health System. Prior to joining TRICARE Management Activity, Dr. Granger led the largest U.S. and multi-national battlefield health system in Dlh Holdings Corp. recent history while serving as Commander, Task Force 44th Medical Command and Command Surgeon for the Multinational Corps Iraq. Presently, Dr. Granger is the President and CEO of The 5Ps, LLC, a healthcare, education, and leadership consultancy he founded following his retirement from the U.S. Army. Dr. Granger received a B.S. Degree from Arkansas State University and earned his medical degree from University of Arkansas School of Medicine. Upon graduation from the University of Arkansas School of Medicine, he was awarded the Henry Kaiser Medical Fellowship for Medical Excellence and Leadership. Dr. Granger is board certified by the American College of Physician Executives, American Board of Medical Quality, American Board of Internal Medicine, Medical Oncology, Hematology, and holds numerous medical certifications. Additionally, Dr. Granger has earned the CERT Certificate in Cybersecurity Oversight from Carnegie Mellon University. A National Association of Corporate Director, Certified Director and Fellow, Dr. Granger currently serves on the board of directors of Cigna Corp., since December 2018 (chair – Compliance Committee and member – Corporate Governance Committee), and Better Therapeutics, Inc. since 2021 (member – Audit Committee). He served on the board of Express Scripts Holding from 2015 until its merger with Cigna Corp. and served on the board of Cerner Corp. from November 2020 to June 2022 (member – Audit Committee and Nominating, Governance and Public Policy Committee). Dr. Granger is also a current and former advisor or member of the board of directors of additional privately-held companies and also serves on the Board of Visitors of the University of Arkansas School of Medicine.
Julie L. Gerberding

Julie L. Gerberding于2017年3月3日被任命为塞纳公司董事会成员。她被任命为Merck&Co.,Inc执行副总裁兼首席耐心官,战略传播,全球公共政策和人口健康。默克“。默克是一家全球性的医疗保健公司,通过其处方药,疫苗,生物疗法和动物保健产品(通过其合资企业直接销售)提供创新的健康解决方案。在此职位上,Gerberding博士负责默克的全球公共政策,企业责任和沟通职能,以及默克基金会和默克母亲项目。 Gerberding博士于2010年1月加入默克,出任默克疫苗总裁,并于2015年12月晋升为战略通信,全球公共政策和人口健康执行副总裁。在加入默克之前,Gerberding博士曾担任美国疾病控制和预防(CDC)从2002 - 2009年,在此之前,担任医疗保健质量促进司司长。在加入疾病预防控制中心之前,Gerberding博士曾是加利福尼亚大学旧金山分校(UCSF)传染病学系的终身教职人员。她继续担任加州大学旧金山分校临床副教授。


Julie L. Gerberding has been a member of the Board of Directors of the Company since March 2017. She has been the Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health of Merck & Co., Inc. "Merck" (NYSE: MRK) since July 2016 and will continue to hold that position until she becomes the Chief Executive Officer of The Foundation for the National Institutes of Health on May 16 2022. Merck is a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. In this position, Dr. Gerberding is responsible for Merck's global public policy, corporate responsibility and communications functions, as well as the Merck Foundation and the Merck for Mothers program. Dr. Gerberding also leads new partnership initiatives that accelerate Merck's ability to contribute to improved population health, a measure of impact that is increasingly valued by governments and other global health organizations.Dr. Gerberding joined Merck as President of Merck Vaccines in January 2010 and was promoted to Executive Vice President for Strategic Communications, Global Public Policy and Population Health in December 2015. Prior to joining Merck, Dr. Gerberding served as Director of the U.S. Centers for Disease Control and Prevention ("CDC") from 2002-2009 and before that served as Director of the Division of Healthcare Quality Promotion. Before joining the CDC, Dr. Gerberding was a tenured faculty member in Infectious Diseases at the University of California at San Francisco ("UCSF"). She continues as an Adjunct Associate Clinical Professor of Medicine at UCSF. Dr. Gerberding is a member of the board of directors of The Foundation for the National Institutes of Health and AfterNext HealthTech Acquisition Corp. ( NYSE: AFTR).
Julie L. Gerberding于2017年3月3日被任命为塞纳公司董事会成员。她被任命为Merck&Co.,Inc执行副总裁兼首席耐心官,战略传播,全球公共政策和人口健康。默克“。默克是一家全球性的医疗保健公司,通过其处方药,疫苗,生物疗法和动物保健产品(通过其合资企业直接销售)提供创新的健康解决方案。在此职位上,Gerberding博士负责默克的全球公共政策,企业责任和沟通职能,以及默克基金会和默克母亲项目。 Gerberding博士于2010年1月加入默克,出任默克疫苗总裁,并于2015年12月晋升为战略通信,全球公共政策和人口健康执行副总裁。在加入默克之前,Gerberding博士曾担任美国疾病控制和预防(CDC)从2002 - 2009年,在此之前,担任医疗保健质量促进司司长。在加入疾病预防控制中心之前,Gerberding博士曾是加利福尼亚大学旧金山分校(UCSF)传染病学系的终身教职人员。她继续担任加州大学旧金山分校临床副教授。
Julie L. Gerberding has been a member of the Board of Directors of the Company since March 2017. She has been the Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health of Merck & Co., Inc. "Merck" (NYSE: MRK) since July 2016 and will continue to hold that position until she becomes the Chief Executive Officer of The Foundation for the National Institutes of Health on May 16 2022. Merck is a global healthcare company that delivers innovative health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. In this position, Dr. Gerberding is responsible for Merck's global public policy, corporate responsibility and communications functions, as well as the Merck Foundation and the Merck for Mothers program. Dr. Gerberding also leads new partnership initiatives that accelerate Merck's ability to contribute to improved population health, a measure of impact that is increasingly valued by governments and other global health organizations.Dr. Gerberding joined Merck as President of Merck Vaccines in January 2010 and was promoted to Executive Vice President for Strategic Communications, Global Public Policy and Population Health in December 2015. Prior to joining Merck, Dr. Gerberding served as Director of the U.S. Centers for Disease Control and Prevention ("CDC") from 2002-2009 and before that served as Director of the Division of Healthcare Quality Promotion. Before joining the CDC, Dr. Gerberding was a tenured faculty member in Infectious Diseases at the University of California at San Francisco ("UCSF"). She continues as an Adjunct Associate Clinical Professor of Medicine at UCSF. Dr. Gerberding is a member of the board of directors of The Foundation for the National Institutes of Health and AfterNext HealthTech Acquisition Corp. ( NYSE: AFTR).
John J. Greisch

John J. Greisch自2019年4月以来一直担任塞纳公司董事会成员。他是Hill-Rom Holdings,Inc.“ Hill-Rom”(纽约证券交易所:HRC)的前总裁兼首席执行官。医疗技术公司,他从2010年1月担任职务,直到2018年5月退休。在加入Hill-Rom之前,Greisch先生曾担任Baxter International,Inc.(“ Baxter”)(纽约证券交易所:BAX)的国际业务总裁。他于2006年至2009年期间担任董事。在他与百特(Baxter)任职期间,他还担任过百特(Baxter)的首席财务官和生物科学事业部总裁。在加入百特之前,他曾担任FleetPride Corporation的总裁兼首席执行官。在此之前,他曾在Interlake公司担任过各种职务,包括担任其材料处理小组总裁。 Greisch先生目前是Catalent,Inc.(纽约证券交易所:CTLT),Carrier Corporation(联合技术公司(纽约证券交易所:UTX)的子公司)和Idorsia Pharmaceuticals Ltd.(六瑞士交易所:IDIA)的董事会成员。 ),并曾在Hill-Rom(NYSE:HRC),Actelion Ltd,TomoTherapy,Inc.(以前是纳斯达克:TOMO)和高级医疗技术协会(AdvaMed)的董事会任职。此外,他还是TPG Capital的高级顾问,还是芝加哥Ann & Robert H. Lurie儿童医院的董事会成员。他获得了西北大学凯洛格管理学院的管理硕士学位和迈阿密大学的学士学位。


John J. Greisch,has been a member of the Board since February 2018 and was appointed as Executive Chair on August 28, 2023. Mr. Greisch retired in May 2018 from his position as President and Chief Executive Officer of Hill-Rom Holdings, Inc., a position that he had held since 2010. Prior to that, Mr. Greisch was President International Operations for Baxter International, Inc., a position he held beginning in 2006. During his seven-year tenure with Baxter, he also served as Baxter's Chief Financial Officer and as President of Baxter's BioScience division. Before his time with Baxter, Mr. Greisch was President and Chief Executive Officer for FleetPride Corporation in Deerfield, Illinois, an independent after-market distribution company serving the transportation industry. Prior to his tenure at FleetPride, he held various positions at The Interlake Corporation, including serving as President of its Materials Handling Group. Mr. Greisch currently serves as chairman of the board of Viant Medical LLC and as lead independent director on the board of Carrier Corporation. He previously served on the boards of Cerner Corporation, Idorsia Pharmaceuticals Ltd., Hill-Rom Holdings, Inc., Actelion Ltd, and TomoTherapy, Inc. Additionally, he serves as a senior advisor to TPG Capital and is on the board of directors for Ann & Robert H. Lurie Children's Hospital of Chicago. He received a Masters in Management from the Kellogg School of Management at Northwestern University and a B.S. degree from Miami University.
John J. Greisch自2019年4月以来一直担任塞纳公司董事会成员。他是Hill-Rom Holdings,Inc.“ Hill-Rom”(纽约证券交易所:HRC)的前总裁兼首席执行官。医疗技术公司,他从2010年1月担任职务,直到2018年5月退休。在加入Hill-Rom之前,Greisch先生曾担任Baxter International,Inc.(“ Baxter”)(纽约证券交易所:BAX)的国际业务总裁。他于2006年至2009年期间担任董事。在他与百特(Baxter)任职期间,他还担任过百特(Baxter)的首席财务官和生物科学事业部总裁。在加入百特之前,他曾担任FleetPride Corporation的总裁兼首席执行官。在此之前,他曾在Interlake公司担任过各种职务,包括担任其材料处理小组总裁。 Greisch先生目前是Catalent,Inc.(纽约证券交易所:CTLT),Carrier Corporation(联合技术公司(纽约证券交易所:UTX)的子公司)和Idorsia Pharmaceuticals Ltd.(六瑞士交易所:IDIA)的董事会成员。 ),并曾在Hill-Rom(NYSE:HRC),Actelion Ltd,TomoTherapy,Inc.(以前是纳斯达克:TOMO)和高级医疗技术协会(AdvaMed)的董事会任职。此外,他还是TPG Capital的高级顾问,还是芝加哥Ann & Robert H. Lurie儿童医院的董事会成员。他获得了西北大学凯洛格管理学院的管理硕士学位和迈阿密大学的学士学位。
John J. Greisch,has been a member of the Board since February 2018 and was appointed as Executive Chair on August 28, 2023. Mr. Greisch retired in May 2018 from his position as President and Chief Executive Officer of Hill-Rom Holdings, Inc., a position that he had held since 2010. Prior to that, Mr. Greisch was President International Operations for Baxter International, Inc., a position he held beginning in 2006. During his seven-year tenure with Baxter, he also served as Baxter's Chief Financial Officer and as President of Baxter's BioScience division. Before his time with Baxter, Mr. Greisch was President and Chief Executive Officer for FleetPride Corporation in Deerfield, Illinois, an independent after-market distribution company serving the transportation industry. Prior to his tenure at FleetPride, he held various positions at The Interlake Corporation, including serving as President of its Materials Handling Group. Mr. Greisch currently serves as chairman of the board of Viant Medical LLC and as lead independent director on the board of Carrier Corporation. He previously served on the boards of Cerner Corporation, Idorsia Pharmaceuticals Ltd., Hill-Rom Holdings, Inc., Actelion Ltd, and TomoTherapy, Inc. Additionally, he serves as a senior advisor to TPG Capital and is on the board of directors for Ann & Robert H. Lurie Children's Hospital of Chicago. He received a Masters in Management from the Kellogg School of Management at Northwestern University and a B.S. degree from Miami University.
Melinda J. Mount

Melinda J. Mount自2019年4月以来一直是公司董事会成员。Mount女士最近担任消费技术和可穿戴产品公司AliphCom,Inc. d / b / a Jawbone的总裁,她于2013年6月至2014年2月任职。此前,她曾于2010年至2013年5月在微软公司(“微软”)(纳斯达克股票代码:MSFT)担任各种高级职位,包括公司副总裁兼在线服务部首席财务官。从2006年至2010年,她担任娱乐与设备事业部运营与财务副总裁兼首席财务官。在加入微软之前,Mount女士曾在时代华纳公司(Time Warner,Inc。)担任战略与发展副总裁。 Warner”(原纽约证券交易所股票代码:TWX),从1995年至2001年,然后担任AOL Inc.(原纽约证券交易所股票交易所:AOL)英国分公司的执行副总裁兼联合董事总经理。 r以及时代华纳(Time Warner)的子公司,从2001年至2003年。在此之前,她从1987年至1995年担任摩根士丹利(NYSE:MS)的并购副总裁。Mount女士曾担任董事会成员自2016年4月起担任Technicolor SA(TCH:FP)董事,目前担任董事会副主席,并自2014年12月起担任Learning Care Group,Inc.的董事会成员。


Melinda J. Mount has been a member of the Board of Directors of the Company since April 2019. Ms. Mount most recently served as President of AliphCom, Inc. d/b/a Jawbone, a consumer technology and wearable products company, which position she held from June 2013 until February 2014. Previously, she held various senior level positions at Microsoft Corporation ("Microsoft") (Nasdaq: MSFT), including Corporate Vice President and Chief Financial Officer of the Online Services Division, from 2010 until May 2013 and Corporate Vice President of Operations and Finance and Chief Financial Officer of the Entertainment and Device Division, from 2006 until 2010. Prior to joining Microsoft, Ms. Mount served as the Vice President of Strategy and Development at Time Warner, Inc. ("Time Warner") (formerly NYSE: TWX), from 1995 until 2001 and then as Executive Vice President and Co-Managing Director of the United Kingdom Division of AOL Inc. (formerly NYSE: AOL), a web portal and online service provider and a subsidiary of Time Warner, from 2001 until 2003. Prior to that, she served as Vice President of Mergers and Acquisitions at Morgan Stanley (NYSE: MS) from 1987 until 1995. Ms. Mount has served as a member of the board of directors of Technicolor S.A. (TCH: FP) since April 2016 and currently serves as Vice Chairman of the board. She is also a member of the board of directors of Group Nine Acquisition Corp (Nasdaq: GNAC), Zayo Group Holdings, and the Learning Care Group, Inc.
Melinda J. Mount自2019年4月以来一直是公司董事会成员。Mount女士最近担任消费技术和可穿戴产品公司AliphCom,Inc. d / b / a Jawbone的总裁,她于2013年6月至2014年2月任职。此前,她曾于2010年至2013年5月在微软公司(“微软”)(纳斯达克股票代码:MSFT)担任各种高级职位,包括公司副总裁兼在线服务部首席财务官。从2006年至2010年,她担任娱乐与设备事业部运营与财务副总裁兼首席财务官。在加入微软之前,Mount女士曾在时代华纳公司(Time Warner,Inc。)担任战略与发展副总裁。 Warner”(原纽约证券交易所股票代码:TWX),从1995年至2001年,然后担任AOL Inc.(原纽约证券交易所股票交易所:AOL)英国分公司的执行副总裁兼联合董事总经理。 r以及时代华纳(Time Warner)的子公司,从2001年至2003年。在此之前,她从1987年至1995年担任摩根士丹利(NYSE:MS)的并购副总裁。Mount女士曾担任董事会成员自2016年4月起担任Technicolor SA(TCH:FP)董事,目前担任董事会副主席,并自2014年12月起担任Learning Care Group,Inc.的董事会成员。
Melinda J. Mount has been a member of the Board of Directors of the Company since April 2019. Ms. Mount most recently served as President of AliphCom, Inc. d/b/a Jawbone, a consumer technology and wearable products company, which position she held from June 2013 until February 2014. Previously, she held various senior level positions at Microsoft Corporation ("Microsoft") (Nasdaq: MSFT), including Corporate Vice President and Chief Financial Officer of the Online Services Division, from 2010 until May 2013 and Corporate Vice President of Operations and Finance and Chief Financial Officer of the Entertainment and Device Division, from 2006 until 2010. Prior to joining Microsoft, Ms. Mount served as the Vice President of Strategy and Development at Time Warner, Inc. ("Time Warner") (formerly NYSE: TWX), from 1995 until 2001 and then as Executive Vice President and Co-Managing Director of the United Kingdom Division of AOL Inc. (formerly NYSE: AOL), a web portal and online service provider and a subsidiary of Time Warner, from 2001 until 2003. Prior to that, she served as Vice President of Mergers and Acquisitions at Morgan Stanley (NYSE: MS) from 1987 until 1995. Ms. Mount has served as a member of the board of directors of Technicolor S.A. (TCH: FP) since April 2016 and currently serves as Vice Chairman of the board. She is also a member of the board of directors of Group Nine Acquisition Corp (Nasdaq: GNAC), Zayo Group Holdings, and the Learning Care Group, Inc.
William D. Zollars

William D. Zollars先生自2005年5月起出任本公司董事。1999年11月至2011年7月,他曾是YRC环球公司( YRC Worldwide,现称“YRC Freight”)的前任主席、总裁兼首席执行官。YRC货运公司专门提供运输和全球物流服务。1996年9月至1999年11月,Zollars先生曾担任黄海运输公司(Yellow Transportation, Inc. )的总裁。1994至1996年,Zollars先生曾担任莱德综合物流(Ryder Integrated Logistics)的高级副总裁。在此之前,Zollars先生曾在柯达公司(Eastman Kodak。)担任各种行政职务。Zollars先生担任信诺公司(CIGNA Corporation)和普洛斯公司( Prologis, Inc.)的董事。Zollars先生还是大堪萨斯城联合之路(United Way of Greater Kansas City)和明尼苏达大学( University of Minnesota。)的卡尔森管理学院(The Carlson School of Management )的董事会成员。


William D. Zollars has been a member of the Board of Directors of the Company since May 2005 and served as Lead Independent Director from April 2019 until October 2021 when he was appointed as the Chairman of the Board. He is the former Chairman, President and Chief Executive Officer of YRC Worldwide now known as Yellow Corporation (Nasdaq: YELL), which positions he held from November 1999 to July 2011. Prior to that, Mr. Zollars served as President of Yellow Transportation, Inc. from September 1996 through November 1999. From 1994 to 1996 Mr. Zollars was Senior Vice President of Ryder Integrated Logistics, and prior to that, Mr. Zollars held various executive positions with Eastman Kodak.Mr. Zollars also serves on the board of directors of Prologis, Inc. (NYSE: PLD) and served on the board of directors of CIGNA Corporation (NYSE: CI) until November 2019.
William D. Zollars先生自2005年5月起出任本公司董事。1999年11月至2011年7月,他曾是YRC环球公司( YRC Worldwide,现称“YRC Freight”)的前任主席、总裁兼首席执行官。YRC货运公司专门提供运输和全球物流服务。1996年9月至1999年11月,Zollars先生曾担任黄海运输公司(Yellow Transportation, Inc. )的总裁。1994至1996年,Zollars先生曾担任莱德综合物流(Ryder Integrated Logistics)的高级副总裁。在此之前,Zollars先生曾在柯达公司(Eastman Kodak。)担任各种行政职务。Zollars先生担任信诺公司(CIGNA Corporation)和普洛斯公司( Prologis, Inc.)的董事。Zollars先生还是大堪萨斯城联合之路(United Way of Greater Kansas City)和明尼苏达大学( University of Minnesota。)的卡尔森管理学院(The Carlson School of Management )的董事会成员。
William D. Zollars has been a member of the Board of Directors of the Company since May 2005 and served as Lead Independent Director from April 2019 until October 2021 when he was appointed as the Chairman of the Board. He is the former Chairman, President and Chief Executive Officer of YRC Worldwide now known as Yellow Corporation (Nasdaq: YELL), which positions he held from November 1999 to July 2011. Prior to that, Mr. Zollars served as President of Yellow Transportation, Inc. from September 1996 through November 1999. From 1994 to 1996 Mr. Zollars was Senior Vice President of Ryder Integrated Logistics, and prior to that, Mr. Zollars held various executive positions with Eastman Kodak.Mr. Zollars also serves on the board of directors of Prologis, Inc. (NYSE: PLD) and served on the board of directors of CIGNA Corporation (NYSE: CI) until November 2019.
George A. Riedel

自2013年5月George A. Riedel 在董事会任职,Riedel担任Montreal-based Accedian Networks公司董事会的主席,他自2010年在该公司担任董事。自2011年起Riedel先生担任PeerApp公司董事会成员,从2009年直到它在2010年出售给IBM,Riedel先生担任Blade网络科技公司的董事会成员,在2006年3月Riedel先生加盟北电网络公司(Nortel Networks Corporation),是一家公开上市的跨国公司,电信设备制造商“Nortel”,并担任一部分周转团队的首席战略官。Nortel在加拿大的重组机制,和公司信贷安排,美国破产法及英国的1986年破产法案下发起信贷保护后,他的职位发生了变化,随后,在以色列,他通过一系列的业务引导各种运营商和企业业务单位的出售/重组,使公司成为业内领先厂商,例如Ericsson, Avaya and Ciena公司的出售/重组。Riedel先生领导创建独立的业务部门,能提供相关的损益表和资产负债表,并指定主要的在用专利,使销售团队更加努力。 2010年,Riedel先生的职务变为业务部门总裁和首席战略官,那时他负责将留存的6500项专利和专利申请盈利化,并管理几个为销售成立的业务部门的损益情况。 2011项专利的出售为苹果,爱立信,RIM,微软和EMC财团带来了前所未有的45亿的销售业绩。加入Nortel之前,从2003年到2006年Riedel先生是Juniper网络公司的战略与企业发展部副总裁,这是一家网络产品公开交易的设计,开发和制造商,之前,Riedel先生是一家全球性管理咨询公司麦肯锡公司的董事,在那里他花了15年时间在一系列战略和增长的问题上服务于亚洲和北美的电信和技术行业的客户。 Riedel先生获得弗吉尼亚大学(University of Virginia)机械工程特优学士学位和哈佛商学院(Harvard Business School)的MBA学位。


George A. Riedel has been a member of the Board of Directors of the Company since April 2019. Mr. Riedel has served as a Senior Lecturer at Harvard Business School since January 2018. Since June 2020 he has served on the Board of Directors of Infinera Corporation Nasdaq: INFN, a global supplier of networking solutions comprised of networking equipment, software and services, and was named Chairman of the Infinera Board of Directors in November 2020. Mr. Riedel has also served since January 2021 as Chairman of the Board of Juvare, a provider of emergency preparedness and response software solutions. Mr. Riedel has also served on the Board of Directors of Xperi Corporation (Nasdaq:XPER) (f/k/a Tessera Holding Corporation ("Tessera Holding")), a creator, developer and licensor of innovative audio, computational imaging, computer vision and semiconductor packaging and interconnect technologies, since December 2016 when Tessera Technologies, Inc. ("Tessera") and DTS, Inc. became wholly owned subsidiaries of Tessera Holding pursuant to a merger. Prior to the merger, he had served on the Board of Directors of Tessera (formerly Nasdaq:TSRA) since May 2013. Mr. Riedel previously served as the Chairman of the Board of Directors of Accedian Networks Inc., a performance assurance solution specialist for mobile networks and enterprise-to-data center connectivity, from 2010 until March 2017 when it was sold to Bridge Growth Partners. From 2013 to 2017 he served as the Chairman and Chief Executive Officer of Cloudmark, Inc., a leader in security, protecting traffic, data and infrastructure from network threats. He also previously served on the Boards of Directors of NextDocs Corporation, a clinical trial and compliance management software company from July 2013 to April 2015 PeerApp Ltd, an optimized video content delivery service to network operators and providers, from 2011 to September 2015 and Blade Network Technologies, a top of rack switch vendor, from 2009 until its sale to IBM in 2010. Mr. Riedel's career has also included various senior management positions at Nortel Networks Corporation, a then publicly traded, global telecommunications equipment manufacturer ("Nortel"). In March 2006 Mr. Riedel joined Nortel as part of the turnaround team as the Chief Strategy Officer. His role changed after Nortel initiated industry players such as Ericsson, Avaya and Ciena. Mr. Riedel led the efforts to create standalone business units, carve out the relevant P&L and balance sheet elements and assign predominately used patents to enable sales of the assets. In 2010 Mr. Riedel's role changed to President of Business Units and Chief Strategy Officer as he took leadership of the effort to monetize the remaining 6500 patents and applications patents, as well as manage the P&L for several business units that were held for sale. The 2011 patent sale led to an unprecedented transaction of $4.5 billion to a consortium of Apple, Ericsson, RIM, Microsoft and EMC. Prior to Nortel, Mr. Riedel was the Vice President of Strategy and Corporate Development of Juniper Networks, Inc. (NYSE:JNPR), a designer, developer and manufacturer of networking products, from 2003 until 2006 where he led the acquisition of Netscreen Technologies. Mr. Riedel was also previously a Senior Partner at McKinsey & Company, a global management consulting firm, where he spent 15 years serving clients in the telecom and technology sectors in Asia and North America on a range of strategy and growth issues.
自2013年5月George A. Riedel 在董事会任职,Riedel担任Montreal-based Accedian Networks公司董事会的主席,他自2010年在该公司担任董事。自2011年起Riedel先生担任PeerApp公司董事会成员,从2009年直到它在2010年出售给IBM,Riedel先生担任Blade网络科技公司的董事会成员,在2006年3月Riedel先生加盟北电网络公司(Nortel Networks Corporation),是一家公开上市的跨国公司,电信设备制造商“Nortel”,并担任一部分周转团队的首席战略官。Nortel在加拿大的重组机制,和公司信贷安排,美国破产法及英国的1986年破产法案下发起信贷保护后,他的职位发生了变化,随后,在以色列,他通过一系列的业务引导各种运营商和企业业务单位的出售/重组,使公司成为业内领先厂商,例如Ericsson, Avaya and Ciena公司的出售/重组。Riedel先生领导创建独立的业务部门,能提供相关的损益表和资产负债表,并指定主要的在用专利,使销售团队更加努力。 2010年,Riedel先生的职务变为业务部门总裁和首席战略官,那时他负责将留存的6500项专利和专利申请盈利化,并管理几个为销售成立的业务部门的损益情况。 2011项专利的出售为苹果,爱立信,RIM,微软和EMC财团带来了前所未有的45亿的销售业绩。加入Nortel之前,从2003年到2006年Riedel先生是Juniper网络公司的战略与企业发展部副总裁,这是一家网络产品公开交易的设计,开发和制造商,之前,Riedel先生是一家全球性管理咨询公司麦肯锡公司的董事,在那里他花了15年时间在一系列战略和增长的问题上服务于亚洲和北美的电信和技术行业的客户。 Riedel先生获得弗吉尼亚大学(University of Virginia)机械工程特优学士学位和哈佛商学院(Harvard Business School)的MBA学位。
George A. Riedel has been a member of the Board of Directors of the Company since April 2019. Mr. Riedel has served as a Senior Lecturer at Harvard Business School since January 2018. Since June 2020 he has served on the Board of Directors of Infinera Corporation Nasdaq: INFN, a global supplier of networking solutions comprised of networking equipment, software and services, and was named Chairman of the Infinera Board of Directors in November 2020. Mr. Riedel has also served since January 2021 as Chairman of the Board of Juvare, a provider of emergency preparedness and response software solutions. Mr. Riedel has also served on the Board of Directors of Xperi Corporation (Nasdaq:XPER) (f/k/a Tessera Holding Corporation ("Tessera Holding")), a creator, developer and licensor of innovative audio, computational imaging, computer vision and semiconductor packaging and interconnect technologies, since December 2016 when Tessera Technologies, Inc. ("Tessera") and DTS, Inc. became wholly owned subsidiaries of Tessera Holding pursuant to a merger. Prior to the merger, he had served on the Board of Directors of Tessera (formerly Nasdaq:TSRA) since May 2013. Mr. Riedel previously served as the Chairman of the Board of Directors of Accedian Networks Inc., a performance assurance solution specialist for mobile networks and enterprise-to-data center connectivity, from 2010 until March 2017 when it was sold to Bridge Growth Partners. From 2013 to 2017 he served as the Chairman and Chief Executive Officer of Cloudmark, Inc., a leader in security, protecting traffic, data and infrastructure from network threats. He also previously served on the Boards of Directors of NextDocs Corporation, a clinical trial and compliance management software company from July 2013 to April 2015 PeerApp Ltd, an optimized video content delivery service to network operators and providers, from 2011 to September 2015 and Blade Network Technologies, a top of rack switch vendor, from 2009 until its sale to IBM in 2010. Mr. Riedel's career has also included various senior management positions at Nortel Networks Corporation, a then publicly traded, global telecommunications equipment manufacturer ("Nortel"). In March 2006 Mr. Riedel joined Nortel as part of the turnaround team as the Chief Strategy Officer. His role changed after Nortel initiated industry players such as Ericsson, Avaya and Ciena. Mr. Riedel led the efforts to create standalone business units, carve out the relevant P&L and balance sheet elements and assign predominately used patents to enable sales of the assets. In 2010 Mr. Riedel's role changed to President of Business Units and Chief Strategy Officer as he took leadership of the effort to monetize the remaining 6500 patents and applications patents, as well as manage the P&L for several business units that were held for sale. The 2011 patent sale led to an unprecedented transaction of $4.5 billion to a consortium of Apple, Ericsson, RIM, Microsoft and EMC. Prior to Nortel, Mr. Riedel was the Vice President of Strategy and Corporate Development of Juniper Networks, Inc. (NYSE:JNPR), a designer, developer and manufacturer of networking products, from 2003 until 2006 where he led the acquisition of Netscreen Technologies. Mr. Riedel was also previously a Senior Partner at McKinsey & Company, a global management consulting firm, where he spent 15 years serving clients in the telecom and technology sectors in Asia and North America on a range of strategy and growth issues.
Mitchell E. Daniels, Jr.

Mitchell E. Daniels, Jr.自2013年起担任普渡大学校长,并于2005年至2013年担任印第安纳州州长。从1990年至2000年,Daniels先生在Eli Lilly and Company工作,担任北美总裁的行政职务。 制药业务和企业战略与政策高级副总裁。 Daniels先生还是Cerner Corp.Areas of Expertise的董事:首席执行官/高级官员; 财会;治理/板; 政府和利益相关者关系; 策略计划。


Mitchell E. Daniels, Jr. has been President of Purdue University since 2013 and served as Governor of Indiana from 2005 to 2013. From 1990 to 2000 Mr. Daniels worked for Eli Lilly and Company, holding the executive positions of President of North American Pharmaceutical Operations and Senior Vice President of Corporate Strategy and Policy. Mr. Daniels is also a director of Cerner Corporation.CEO/Senior Officer; Finance and Accounting; Governance/Board; Governmental and Stakeholder Relations; Strategic Planning.
Mitchell E. Daniels, Jr.自2013年起担任普渡大学校长,并于2005年至2013年担任印第安纳州州长。从1990年至2000年,Daniels先生在Eli Lilly and Company工作,担任北美总裁的行政职务。 制药业务和企业战略与政策高级副总裁。 Daniels先生还是Cerner Corp.Areas of Expertise的董事:首席执行官/高级官员; 财会;治理/板; 政府和利益相关者关系; 策略计划。
Mitchell E. Daniels, Jr. has been President of Purdue University since 2013 and served as Governor of Indiana from 2005 to 2013. From 1990 to 2000 Mr. Daniels worked for Eli Lilly and Company, holding the executive positions of President of North American Pharmaceutical Operations and Senior Vice President of Corporate Strategy and Policy. Mr. Daniels is also a director of Cerner Corporation.CEO/Senior Officer; Finance and Accounting; Governance/Board; Governmental and Stakeholder Relations; Strategic Planning.
R. Halsey Wise

R. Halsey Wise,2014年3月被选为公司董事,也是董事会薪酬委员会和信息技术委员会委员。他是Lime Barrel Advisors公司(Lime Barrel Advisors, Inc.)创始人和首席执行官,这是一家私人投资公司。他在领先的全球科技和软件公司有担任高级执行官丰富的职业生涯经验。从2003年到2010年,他是Intergraph公司(Intergraph Corporation)担任董事长和首席执行官,这是一家全球工程和地理空间软件供应商。从2000年到2003年,他是北美解决方案公司总裁和首席执行官,这是澳大利亚最大的一家软件公司。从1997年到2000年,他是Computer Management Sciences公司总裁和首席运营官,这是一家信息技术软件和服务公司,该公司被Computer Associates International公司收购,在那里他担任北美全球专业服务总经理。在那之前,他是Robinson-Humphrey公司(The Robinson-Humphrey Company)投资银行家,这是一家专注于软件和科技的公司。他在西北大学凯洛格商学院(Northwestern University's Kellogg School of Management)财务和市场硕士学位,在弗吉尼亚大学(the University of Virginia)历史学学士学位。


R. Halsey Wise,has been Afternext Healthtech Acquisition Corp. Chief Executive Officer and Chairman since July 2021. Mr. Wise is also Chairman and Chief Executive of Lime Barrel Advisors, LLC, a private investment firm, which he founded and where he has served since October 2010. Mr. Wise brings nearly 30 years of leadership, HealthTech, Software and financial experience to AfterNext in addition to valuable experience having led several successful business transformation, growth and value creation initiatives. Mr. Wise served as chairman, CEO, or president of three public companies, including serving as chairman and CEO of MedAssets Inc., a leading healthcare technology performance improvement Company, from February 2015 to February 2016. Prior to that, Mr. Wise served as chairman, president and CEO of Intergraph Corporation from July 2003 to October 2010; chairman, CEO and president of the North American region for Solution 6 Holdings, Ltd. from December 1999 to June 2003; general manager of the North American region for Global Services for CA, Inc. from April 1999 to December 1999; and president and COO of Computer Management Sciences, Inc. from August 1997 to April 1999. Mr. Wise served on the board of directors of publicly held technology companies, Cerner Corporation from April 2019 until its sale to Oracle Corp in June 2022 and AspenTech from July 2016 until its sale to Emerson Electric in May 2022. He has also served on the board of directors of WellSky, a private health care information technology company, since January 2019. Previously, Mr. Wise also served on boards of directors at publicly held companies including Cotiviti Health Inc. from December 2017 to August 2018, MedAssets, Inc. from March 2014 to February 2016, Acxiom Corporation from September 2006 to December 2011 and Intergraph Corporation from July 2003 to October 2010. Mr. Wise has also served as a senior advisor for HealthTech to TPG Capital, a global private investment firm, since October 2019. As a result of Wise's leadership at Intergraph, Mr. Wise is recognized as one of the software industry leaders in the disciplines of transformative leadership, innovation, value creation, capital allocation and performance-based cultures. In 2010, Wise received the Ernst & Young Entrepreneur of the Year Award in the technology category in Alabama/Georgia/Tennessee. In 1994, Mr. Wise began his career as an investment banker specializing in software and technology as a Vice President with The Robinson-Humphrey Company. Mr. Wise received an MBA in finance and marketing from the J.L. Kellogg Graduate School of Management at Northwestern University and a bachelor's degree in history from the University of Virginia.
R. Halsey Wise,2014年3月被选为公司董事,也是董事会薪酬委员会和信息技术委员会委员。他是Lime Barrel Advisors公司(Lime Barrel Advisors, Inc.)创始人和首席执行官,这是一家私人投资公司。他在领先的全球科技和软件公司有担任高级执行官丰富的职业生涯经验。从2003年到2010年,他是Intergraph公司(Intergraph Corporation)担任董事长和首席执行官,这是一家全球工程和地理空间软件供应商。从2000年到2003年,他是北美解决方案公司总裁和首席执行官,这是澳大利亚最大的一家软件公司。从1997年到2000年,他是Computer Management Sciences公司总裁和首席运营官,这是一家信息技术软件和服务公司,该公司被Computer Associates International公司收购,在那里他担任北美全球专业服务总经理。在那之前,他是Robinson-Humphrey公司(The Robinson-Humphrey Company)投资银行家,这是一家专注于软件和科技的公司。他在西北大学凯洛格商学院(Northwestern University's Kellogg School of Management)财务和市场硕士学位,在弗吉尼亚大学(the University of Virginia)历史学学士学位。
R. Halsey Wise,has been Afternext Healthtech Acquisition Corp. Chief Executive Officer and Chairman since July 2021. Mr. Wise is also Chairman and Chief Executive of Lime Barrel Advisors, LLC, a private investment firm, which he founded and where he has served since October 2010. Mr. Wise brings nearly 30 years of leadership, HealthTech, Software and financial experience to AfterNext in addition to valuable experience having led several successful business transformation, growth and value creation initiatives. Mr. Wise served as chairman, CEO, or president of three public companies, including serving as chairman and CEO of MedAssets Inc., a leading healthcare technology performance improvement Company, from February 2015 to February 2016. Prior to that, Mr. Wise served as chairman, president and CEO of Intergraph Corporation from July 2003 to October 2010; chairman, CEO and president of the North American region for Solution 6 Holdings, Ltd. from December 1999 to June 2003; general manager of the North American region for Global Services for CA, Inc. from April 1999 to December 1999; and president and COO of Computer Management Sciences, Inc. from August 1997 to April 1999. Mr. Wise served on the board of directors of publicly held technology companies, Cerner Corporation from April 2019 until its sale to Oracle Corp in June 2022 and AspenTech from July 2016 until its sale to Emerson Electric in May 2022. He has also served on the board of directors of WellSky, a private health care information technology company, since January 2019. Previously, Mr. Wise also served on boards of directors at publicly held companies including Cotiviti Health Inc. from December 2017 to August 2018, MedAssets, Inc. from March 2014 to February 2016, Acxiom Corporation from September 2006 to December 2011 and Intergraph Corporation from July 2003 to October 2010. Mr. Wise has also served as a senior advisor for HealthTech to TPG Capital, a global private investment firm, since October 2019. As a result of Wise's leadership at Intergraph, Mr. Wise is recognized as one of the software industry leaders in the disciplines of transformative leadership, innovation, value creation, capital allocation and performance-based cultures. In 2010, Wise received the Ernst & Young Entrepreneur of the Year Award in the technology category in Alabama/Georgia/Tennessee. In 1994, Mr. Wise began his career as an investment banker specializing in software and technology as a Vice President with The Robinson-Humphrey Company. Mr. Wise received an MBA in finance and marketing from the J.L. Kellogg Graduate School of Management at Northwestern University and a bachelor's degree in history from the University of Virginia.

高管简历

中英对照 |  中文 |  英文
David T. Feinberg

David T. Feinberg,2010年3月起担任本公司董事。他自2011年7月起,担任UCLA Health System的总裁;2007年7月起,担任UCLA Hospital System的首席执行官,及协理副校长。担任上述职务之前,他是Resnick Neuropsychiatric Hospital NPH at UCLA的医疗总监。他是委员会认证的,儿童和青少年精神病学、成人精神病学和成瘾精神病方面的专业人士。他是 David Geffen School of Medicine at UCLA的临床精神病学教授。他现为Douglas Emmett, Inc.的董事,这是纽交所上市的房地产投资信托基金。1984年,他以优异的成绩毕业于University of California, Berkeley的经济学专业;1989年,以优等生毕业于University of Health Sciences/The Chicago Medical School。2002年,他从获得了Pepperdine University工商管理硕士学位。他当选为董事,是由于他对于医疗行业的丰富知识,以及管理大型国际知名医院系统的经验。


David T. Feinberg,was initially elected to the Board in March 2022. Dr. Feinberg is Chairman of Oracle Health, where he is committed to making healthcare more accessible, affordable, and equitable. His work advances thought leadership and strategy related to unleashing the healing power of data through an open and connected healthcare ecosystem. Previously, Dr. Feinberg served as President and Chief Executive Officer and member of the Board of Directors of Cerner Corporation (Cerner), which is now Oracle Health. In that role Dr. Feinberg focused on delivering tools and technology to help caregivers optimize the health of their patients and communities.Dr. Feinberg joined Cerner from Google, where he held the position of Vice President of Google Health since 2019 and led Google's worldwide health efforts, bringing together groups from across Google and Alphabet that Humana Inc. ed artificial intelligence, product expertise and hardware to tackle some of healthcare's biggest challenges, and was responsible for organizing and innovating Google's various healthcare initiatives. Prior to Google, he served as President and CEO of Geisinger Health where he led an operational turnaround, and pushed the Humana Inc. e of new platforms and tools, including an IT system called a Unified Data Architecture that allowed the company to integrate big data into existing data analytics and management systems. During his Geisinger tenure, Dr. Feinberg also introduced programs and services to put a greater focus on precision medicine and better patient care. Prior to Geisinger, Dr. Feinberg worked at UCLA for more than 20 years and served in a number of leadership roles, including President, CEO and Associate Vice Chancellor of UCLA Health Sciences, Vice Chancellor and CEO for the UCLA Hospital System, and CEO of UCLA's Ronald Reagan Medical Center.Dr. Feinberg earned his undergraduate degree at the University of California, Berkeley. He graduated with distinction from the University of Health Sciences/Chicago Medical School. He completed an internship in pediatrics at Loyola University Medical Center, and residency and fellowship training in psychiatry, addiction psychiatry, and child and adolescent psychiatry at the UCLA School of Medicine. He earned a Master of Business Administration from Pepperdine University. Dr. Feinberg is a member of the Alpha Omega Alpha Medical Honor Society, a Distinguished Fellow of American Psychiatric Association and received the Cancro Academic Leadership Award from the American Academy of Child & Adolescent Psychiatry. Dr. Feinberg also serves on the Board of Directors of Douglas Emmett Inc.
David T. Feinberg,2010年3月起担任本公司董事。他自2011年7月起,担任UCLA Health System的总裁;2007年7月起,担任UCLA Hospital System的首席执行官,及协理副校长。担任上述职务之前,他是Resnick Neuropsychiatric Hospital NPH at UCLA的医疗总监。他是委员会认证的,儿童和青少年精神病学、成人精神病学和成瘾精神病方面的专业人士。他是 David Geffen School of Medicine at UCLA的临床精神病学教授。他现为Douglas Emmett, Inc.的董事,这是纽交所上市的房地产投资信托基金。1984年,他以优异的成绩毕业于University of California, Berkeley的经济学专业;1989年,以优等生毕业于University of Health Sciences/The Chicago Medical School。2002年,他从获得了Pepperdine University工商管理硕士学位。他当选为董事,是由于他对于医疗行业的丰富知识,以及管理大型国际知名医院系统的经验。
David T. Feinberg,was initially elected to the Board in March 2022. Dr. Feinberg is Chairman of Oracle Health, where he is committed to making healthcare more accessible, affordable, and equitable. His work advances thought leadership and strategy related to unleashing the healing power of data through an open and connected healthcare ecosystem. Previously, Dr. Feinberg served as President and Chief Executive Officer and member of the Board of Directors of Cerner Corporation (Cerner), which is now Oracle Health. In that role Dr. Feinberg focused on delivering tools and technology to help caregivers optimize the health of their patients and communities.Dr. Feinberg joined Cerner from Google, where he held the position of Vice President of Google Health since 2019 and led Google's worldwide health efforts, bringing together groups from across Google and Alphabet that Humana Inc. ed artificial intelligence, product expertise and hardware to tackle some of healthcare's biggest challenges, and was responsible for organizing and innovating Google's various healthcare initiatives. Prior to Google, he served as President and CEO of Geisinger Health where he led an operational turnaround, and pushed the Humana Inc. e of new platforms and tools, including an IT system called a Unified Data Architecture that allowed the company to integrate big data into existing data analytics and management systems. During his Geisinger tenure, Dr. Feinberg also introduced programs and services to put a greater focus on precision medicine and better patient care. Prior to Geisinger, Dr. Feinberg worked at UCLA for more than 20 years and served in a number of leadership roles, including President, CEO and Associate Vice Chancellor of UCLA Health Sciences, Vice Chancellor and CEO for the UCLA Hospital System, and CEO of UCLA's Ronald Reagan Medical Center.Dr. Feinberg earned his undergraduate degree at the University of California, Berkeley. He graduated with distinction from the University of Health Sciences/Chicago Medical School. He completed an internship in pediatrics at Loyola University Medical Center, and residency and fellowship training in psychiatry, addiction psychiatry, and child and adolescent psychiatry at the UCLA School of Medicine. He earned a Master of Business Administration from Pepperdine University. Dr. Feinberg is a member of the Alpha Omega Alpha Medical Honor Society, a Distinguished Fellow of American Psychiatric Association and received the Cancro Academic Leadership Award from the American Academy of Child & Adolescent Psychiatry. Dr. Feinberg also serves on the Board of Directors of Douglas Emmett Inc.
Tracy L. Platt

Tracy L. Platt于2019年7月加入公司,担任执行副总裁兼首席人力资源官。 加入公司之前,普拉特女士在全球医疗保健公司Medtronic Plc担任了近十年的行政人力资源职务,该公司致力于开发和分销医疗器械。 更具体地说,普拉特女士于2009年9月至2019年7月担任美敦力公司人力资源副总裁。她在美敦力公司的最新职务包括其全球运营组织的人力资源领导力,并推动整个企业的运营模式转型。


Tracy L. Platt joined the Company in July 2019 as Executive Vice President and Chief Human Resources Officer. Prior to joining the Company, Ms. Platt spent nearly 10 years in executive HR roles at Medtronic Plc, a global healthcare company that develops and distributes medical devices. More specifically, Ms. Platt was Vice President, Human Resources, Medtronic from September 2009 to July 2019.Her most recent role at Medtronic included HR leadership for its global operations organization and driving an operating model transformation throughout the enterprise.
Tracy L. Platt于2019年7月加入公司,担任执行副总裁兼首席人力资源官。 加入公司之前,普拉特女士在全球医疗保健公司Medtronic Plc担任了近十年的行政人力资源职务,该公司致力于开发和分销医疗器械。 更具体地说,普拉特女士于2009年9月至2019年7月担任美敦力公司人力资源副总裁。她在美敦力公司的最新职务包括其全球运营组织的人力资源领导力,并推动整个企业的运营模式转型。
Tracy L. Platt joined the Company in July 2019 as Executive Vice President and Chief Human Resources Officer. Prior to joining the Company, Ms. Platt spent nearly 10 years in executive HR roles at Medtronic Plc, a global healthcare company that develops and distributes medical devices. More specifically, Ms. Platt was Vice President, Human Resources, Medtronic from September 2009 to July 2019.Her most recent role at Medtronic included HR leadership for its global operations organization and driving an operating model transformation throughout the enterprise.
Travis S. Dalton

Travis S. Dalton于2001年8月加入塞纳公司,担任实践运营经理,自那时起担任各种业务和客户高级领导职务,包括2009年2月起担任客户结果执行官,直到他晋升为副总裁和客户结果执行官,他从2011年3月至2012年12月担任该头衔。Dalton先生的职位在2012年12月扩大,从2012年12月他担任投资者所有部副总裁和联邦总经理,并于2016年3月担任投资者所有部高级副总裁和联邦总经理,该头衔于2017年10月更改为联邦政府高级副总裁兼总经理。他的职务于2018年8月更改为Cerner Government Services的高级副总裁兼总裁。他于2021年1月晋升为Cerner Government Services的执行副总裁,首席客户和服务官兼总裁。在此职位上,Dalton先生负责全球客户关系管理,销售,服务,咨询,支持,托管和客户成功。他还领导Cerner为美国国防部(DoD)和退伍军人事务部(VA)实施新的,可互操作的电子健康记录的工作。


Travis S. Dalton joined the Company in August 2001 as Practice Operations Manager and has held a variety of business and client senior leadership roles since that time, including Client Results Executive from February 2009 until he was promoted to Vice President and Client Results Executive, a title which he held from March 2011 to December 2012. Mr. Dalton's role was expanded in December 2012 and he served as the Vice President, Investor Owned and General Manager Federal from December 2012 until he was promoted to Senior Vice President, Investor Owned and General Manager Federal in March 2016 which title was changed to Senior Vice President and General Manager, Federal Government in October 2017. His role was changed to Senior Vice President and President, Cerner Government Services in August 2018. He was promoted to Executive Vice President, Chief Client and Services Officer and President, Cerner Government Services in January 2021. In this role, Mr. Dalton oversees worldwide client relationship management, sales, services, consulting, support, hosting and client success. He also leads Cerner's work in implementing a new, interoperable electronic health record for the U.S. Departments of Defense (DOD) and Veterans Affairs (VA).
Travis S. Dalton于2001年8月加入塞纳公司,担任实践运营经理,自那时起担任各种业务和客户高级领导职务,包括2009年2月起担任客户结果执行官,直到他晋升为副总裁和客户结果执行官,他从2011年3月至2012年12月担任该头衔。Dalton先生的职位在2012年12月扩大,从2012年12月他担任投资者所有部副总裁和联邦总经理,并于2016年3月担任投资者所有部高级副总裁和联邦总经理,该头衔于2017年10月更改为联邦政府高级副总裁兼总经理。他的职务于2018年8月更改为Cerner Government Services的高级副总裁兼总裁。他于2021年1月晋升为Cerner Government Services的执行副总裁,首席客户和服务官兼总裁。在此职位上,Dalton先生负责全球客户关系管理,销售,服务,咨询,支持,托管和客户成功。他还领导Cerner为美国国防部(DoD)和退伍军人事务部(VA)实施新的,可互操作的电子健康记录的工作。
Travis S. Dalton joined the Company in August 2001 as Practice Operations Manager and has held a variety of business and client senior leadership roles since that time, including Client Results Executive from February 2009 until he was promoted to Vice President and Client Results Executive, a title which he held from March 2011 to December 2012. Mr. Dalton's role was expanded in December 2012 and he served as the Vice President, Investor Owned and General Manager Federal from December 2012 until he was promoted to Senior Vice President, Investor Owned and General Manager Federal in March 2016 which title was changed to Senior Vice President and General Manager, Federal Government in October 2017. His role was changed to Senior Vice President and President, Cerner Government Services in August 2018. He was promoted to Executive Vice President, Chief Client and Services Officer and President, Cerner Government Services in January 2021. In this role, Mr. Dalton oversees worldwide client relationship management, sales, services, consulting, support, hosting and client success. He also leads Cerner's work in implementing a new, interoperable electronic health record for the U.S. Departments of Defense (DOD) and Veterans Affairs (VA).
Daniel P. Devers

Daniel P. Devers于2021年1月被任命为塞纳公司执行副总裁兼首席法律官,自2013年5月起担任高级副总裁兼首席知识产权官。作为Cerner的首席法律官,Devers先生负责监督Cerner的全球法律事务,包括诉讼,知识产权和公司事务。在担任首席法律官之前,Devers先生于2020年2月至2021年1月担任云战略高级副总裁,于2018年4月至2020年2月担任高级副总裁and General Counsel,于2003年至2007年担任知识产权高级公司法律顾问,2002年2月至2003年12月,担任知识产权公司法律顾问。自2020年3月以来,他一直是Cerner执行委员会的成员。加入Cerner之前,Devers先生是Shook,Hardy&Bacon LLP的股权合伙人。他在密苏里大学教授专利法,并在密苏里技术公司的董事会任职三年。


Daniel P. Devers was appointed as Executive Vice President, Chief Legal Officer and Secretary in January 2021 and prior to that had served as Senior Vice President and Chief Intellectual Property Officer since May 2013. As Cerner's Chief Legal Officer, Mr. Devers is responsible for overseeing Cerner's worldwide legal affairs including litigation, intellectual property and corporate matters. Prior to serving as Chief Legal Officer, Mr. Devers served as Senior Vice President - Cloud Strategy from February 2020 to January 2021 Senior Vice President and General Counsel from April 2018 to February 2020 Senior Corporate Counsel - Intellectual Property from 2003 to 2007 and Corporate Counsel - Intellectual Property from February 2002 to December 2003. He has been a member of the Cerner Executive Committee since March 2020. Mr. Devers was an equity partner at Shook, Hardy & Bacon LLP prior to joining Cerner. He taught patent law at the University of Missouri and served a three-year gubernatorial appointment to the Missouri Technology Corporation's Board of Directors.
Daniel P. Devers于2021年1月被任命为塞纳公司执行副总裁兼首席法律官,自2013年5月起担任高级副总裁兼首席知识产权官。作为Cerner的首席法律官,Devers先生负责监督Cerner的全球法律事务,包括诉讼,知识产权和公司事务。在担任首席法律官之前,Devers先生于2020年2月至2021年1月担任云战略高级副总裁,于2018年4月至2020年2月担任高级副总裁and General Counsel,于2003年至2007年担任知识产权高级公司法律顾问,2002年2月至2003年12月,担任知识产权公司法律顾问。自2020年3月以来,他一直是Cerner执行委员会的成员。加入Cerner之前,Devers先生是Shook,Hardy&Bacon LLP的股权合伙人。他在密苏里大学教授专利法,并在密苏里技术公司的董事会任职三年。
Daniel P. Devers was appointed as Executive Vice President, Chief Legal Officer and Secretary in January 2021 and prior to that had served as Senior Vice President and Chief Intellectual Property Officer since May 2013. As Cerner's Chief Legal Officer, Mr. Devers is responsible for overseeing Cerner's worldwide legal affairs including litigation, intellectual property and corporate matters. Prior to serving as Chief Legal Officer, Mr. Devers served as Senior Vice President - Cloud Strategy from February 2020 to January 2021 Senior Vice President and General Counsel from April 2018 to February 2020 Senior Corporate Counsel - Intellectual Property from 2003 to 2007 and Corporate Counsel - Intellectual Property from February 2002 to December 2003. He has been a member of the Cerner Executive Committee since March 2020. Mr. Devers was an equity partner at Shook, Hardy & Bacon LLP prior to joining Cerner. He taught patent law at the University of Missouri and served a three-year gubernatorial appointment to the Missouri Technology Corporation's Board of Directors.
Jerome Labat

Jerome Labat于2020年6月加入塞纳公司,担任执行副总裁兼首席技术官。作为首席技术官,Labat先生负责面向客户的软件产品和技术开发,包括平台和产品开发、现代化和安全。在加入塞纳公司之前,Labat先生于2017年9月至2020年6月担任英国跨国纯企业软件和信息技术公司Micro Focus International Plc的高级副总裁兼首席技术官。在这个职位上,Labat领导了一个全球约500人的组织,除其他外,他还负责Labat公司的产品组合技术和战略愿景,即Micro Focus的解决方案将如何通过数字化转型为客户提供支持,并开发和实施技术和解决方案策略,以支持Micro Focus的数字化转型。在加入Micro Focus之前,Labat先生在惠普企业公司(HPE)工作了五年,他最近的头衔是CTO HPE-软件部门,他于2013年12月至2017年8月担任该职位。在此职位上,Labat先生领导了HPE的云自动化业务。在担任CTO HPW-Software Division之前,Labat先生担任HPE云自动化和管理的副总裁兼总经理,并在其他公司担任各种高级领导职务,包括Intuit Corporation和甲骨文股份有限公司。


Jerome Labat was appointed as Executive Vice President, Chief Legal Officer and Secretary in January 2021 and prior to that had served as Senior Vice President and Chief Intellectual Property Officer since May 2013. As Cerner's Chief Legal Officer, Mr. Devers is responsible for overseeing Cerner's worldwide legal affairs including litigation, intellectual property and corporate matters. Prior to serving as Chief Legal Officer, Mr. Devers served as Senior Vice President - Cloud Strategy from February 2020 to January 2021 Senior Vice President and General Counsel from April 2018 to February 2020 Senior Corporate Counsel - Intellectual Property from 2003 to 2007 and Corporate Counsel - Intellectual Property from February 2002 to December 2003. He has been a member of the Cerner Executive Committee since March 2020. Mr. Devers was an equity partner at Shook, Hardy & Bacon LLP prior to joining Cerner. He taught patent law at the University of Missouri and served a three-year gubernatorial appointment to the Missouri Technology Corporation's Board of Directors.
Jerome Labat于2020年6月加入塞纳公司,担任执行副总裁兼首席技术官。作为首席技术官,Labat先生负责面向客户的软件产品和技术开发,包括平台和产品开发、现代化和安全。在加入塞纳公司之前,Labat先生于2017年9月至2020年6月担任英国跨国纯企业软件和信息技术公司Micro Focus International Plc的高级副总裁兼首席技术官。在这个职位上,Labat领导了一个全球约500人的组织,除其他外,他还负责Labat公司的产品组合技术和战略愿景,即Micro Focus的解决方案将如何通过数字化转型为客户提供支持,并开发和实施技术和解决方案策略,以支持Micro Focus的数字化转型。在加入Micro Focus之前,Labat先生在惠普企业公司(HPE)工作了五年,他最近的头衔是CTO HPE-软件部门,他于2013年12月至2017年8月担任该职位。在此职位上,Labat先生领导了HPE的云自动化业务。在担任CTO HPW-Software Division之前,Labat先生担任HPE云自动化和管理的副总裁兼总经理,并在其他公司担任各种高级领导职务,包括Intuit Corporation和甲骨文股份有限公司。
Jerome Labat was appointed as Executive Vice President, Chief Legal Officer and Secretary in January 2021 and prior to that had served as Senior Vice President and Chief Intellectual Property Officer since May 2013. As Cerner's Chief Legal Officer, Mr. Devers is responsible for overseeing Cerner's worldwide legal affairs including litigation, intellectual property and corporate matters. Prior to serving as Chief Legal Officer, Mr. Devers served as Senior Vice President - Cloud Strategy from February 2020 to January 2021 Senior Vice President and General Counsel from April 2018 to February 2020 Senior Corporate Counsel - Intellectual Property from 2003 to 2007 and Corporate Counsel - Intellectual Property from February 2002 to December 2003. He has been a member of the Cerner Executive Committee since March 2020. Mr. Devers was an equity partner at Shook, Hardy & Bacon LLP prior to joining Cerner. He taught patent law at the University of Missouri and served a three-year gubernatorial appointment to the Missouri Technology Corporation's Board of Directors.
Nasim Afsarmanesh

Nasim Afsarmanesh,于2022年1月加入该公司,担任执行副总裁兼首席卫生官。在加入该公司之前,Afsarmanesh博士自2020年10月起担任加州唯一的学术健康系统奥兰治县UCI Health的首席运营官,并自2018年3月起担任人口健康管理执行官。在这些岗位上,她监督了3000多名员工,并监督了住院和非住院操作,包括非住院护理、住院患者进展工作、临床支持服务、辅助服务、公共安全、建筑和施工、应急管理以及财务;是通过实施数字解决方案推进医疗保健未来的关键驱动力;是机构战略增长和发展的重要伙伴;并制定了组织人口健康战略和行动。从2018年3月到2020年10月,Afsarmanesh博士还担任UCI Health门诊部的首席运营官,管理着一支由1000多人和80多个成本中心组成的团队,领导组织和门诊战略、门诊运营和财务,并为医疗计划制定了战略方向,独立医师协会、Medicare和Medi-Cali;2018年5月至2020年10月担任卫生系统承包负责人,并指导卫生系统的承包工作。在加入UCI Health之前,Afsarmanesh博士曾担任UCLA Health医学部的首席质量官,从2014年7月到2018年2月领导了一项大规模的人口健康倡议。在担任这一职务时,Afsarmanesh博士在医学部制定并执行了人口健康和基于价值观的护理战略。在此之前,Afsarmanesh 博士还曾担任加州大学洛杉矶分校健康部副首席医疗官和加州大学洛杉矶分校神经外科健康部质量与安全执行主任。


Nasim Afsarmanesh, joined the Company in January 2022 as Executive Vice President and Chief Health Officer. Prior to joining the Company, Dr. Afsar served as the Chief Operating Officer of UCI Health, Orange County, California's only academic health system, since October 2020 and as Executive for Population Health Management since March 2018. In these roles, she had oversight for more than 3000 employees and oversaw inpatient and ambulatory operations, including ambulatory care, inpatient progression efforts, clinical support services, ancillary service, public safety, building and construction, and emergency management, and finance; was a key driver for advancing the future of healthcare through implementation of digital solutions; was a vital partner for institutional strategic growth and development; and established organizational population health strategy and operations. Dr. Afsar also served as Chief Operating Officer for Ambulatory Care at UCI Health from March 2018 until October 2020 where she managed a team of over 1000 people and 80 cost centers, led organization and ambulatory strategy and ambulatory operations and finance, and established strategic direction for health plans, independent physician associates, Medicare and Medi-Cali; and as head of Health System Contracting from May 2018 to October 2020 where she also directed the health system's contracting. Prior to joining UCI Health, Dr. Afsar served as Chief Quality Officer for the Department of Medicine at UCLA Health, leading a large-scale population health initiative, from July 2014 until February 2018. In this role, Dr. Afsar developed and executed strategies for population health and value-based care in the Department of Medicine. Prior to that, Dr. Afsar also served as the Associate Chief Medical Officer at UCLA Health and Executive Director of Quality and Safety at UCLA Health Department of Neurosurgery.
Nasim Afsarmanesh,于2022年1月加入该公司,担任执行副总裁兼首席卫生官。在加入该公司之前,Afsarmanesh博士自2020年10月起担任加州唯一的学术健康系统奥兰治县UCI Health的首席运营官,并自2018年3月起担任人口健康管理执行官。在这些岗位上,她监督了3000多名员工,并监督了住院和非住院操作,包括非住院护理、住院患者进展工作、临床支持服务、辅助服务、公共安全、建筑和施工、应急管理以及财务;是通过实施数字解决方案推进医疗保健未来的关键驱动力;是机构战略增长和发展的重要伙伴;并制定了组织人口健康战略和行动。从2018年3月到2020年10月,Afsarmanesh博士还担任UCI Health门诊部的首席运营官,管理着一支由1000多人和80多个成本中心组成的团队,领导组织和门诊战略、门诊运营和财务,并为医疗计划制定了战略方向,独立医师协会、Medicare和Medi-Cali;2018年5月至2020年10月担任卫生系统承包负责人,并指导卫生系统的承包工作。在加入UCI Health之前,Afsarmanesh博士曾担任UCLA Health医学部的首席质量官,从2014年7月到2018年2月领导了一项大规模的人口健康倡议。在担任这一职务时,Afsarmanesh博士在医学部制定并执行了人口健康和基于价值观的护理战略。在此之前,Afsarmanesh 博士还曾担任加州大学洛杉矶分校健康部副首席医疗官和加州大学洛杉矶分校神经外科健康部质量与安全执行主任。
Nasim Afsarmanesh, joined the Company in January 2022 as Executive Vice President and Chief Health Officer. Prior to joining the Company, Dr. Afsar served as the Chief Operating Officer of UCI Health, Orange County, California's only academic health system, since October 2020 and as Executive for Population Health Management since March 2018. In these roles, she had oversight for more than 3000 employees and oversaw inpatient and ambulatory operations, including ambulatory care, inpatient progression efforts, clinical support services, ancillary service, public safety, building and construction, and emergency management, and finance; was a key driver for advancing the future of healthcare through implementation of digital solutions; was a vital partner for institutional strategic growth and development; and established organizational population health strategy and operations. Dr. Afsar also served as Chief Operating Officer for Ambulatory Care at UCI Health from March 2018 until October 2020 where she managed a team of over 1000 people and 80 cost centers, led organization and ambulatory strategy and ambulatory operations and finance, and established strategic direction for health plans, independent physician associates, Medicare and Medi-Cali; and as head of Health System Contracting from May 2018 to October 2020 where she also directed the health system's contracting. Prior to joining UCI Health, Dr. Afsar served as Chief Quality Officer for the Department of Medicine at UCLA Health, leading a large-scale population health initiative, from July 2014 until February 2018. In this role, Dr. Afsar developed and executed strategies for population health and value-based care in the Department of Medicine. Prior to that, Dr. Afsar also served as the Associate Chief Medical Officer at UCLA Health and Executive Director of Quality and Safety at UCLA Health Department of Neurosurgery.
Mark J. Erceg

Mark J. Erceg, 现任Masonite公司的执行副总裁和财务总监。他于2010年6月进入Masonite公司。此前,他在宝洁公司(The Procter & Gamble Company)任职18年,担任了多种高级职务。自2008年至2010年,他在宝洁公司(The Procter & Gamble Company)担任了副总裁和全球投资关系方面的总经理。在担任该职位之前,他在瑞典日内瓦担任西欧织物处理部门的财务董事。


Mark J. Erceg joined the Company in February 2021 as Executive Vice President and Chief Financial Officer. Mr. Erceg joined Cerner after serving as Chief Financial Officer of Tiffany & Co. "Tiffany", from October 2016 to January 2021. In that position, Mr. Erceg served as the principal financial officer for Tiffany. Prior to joining Tiffany, Mr. Erceg held the role of Executive Vice President and Chief Financial Officer for Canadian Pacific Railway Limited, a transcontinental railway, from 2015 to 2016 and Masonite International Corporation, a global manufacturer of commercial and residential doors, from 2010 to 2015. Previously, Mr. Erceg held finance, market strategy, general management and global investor relations positions at The Procter & Gamble Company during his tenure there from 1992 to 2010.
Mark J. Erceg, 现任Masonite公司的执行副总裁和财务总监。他于2010年6月进入Masonite公司。此前,他在宝洁公司(The Procter & Gamble Company)任职18年,担任了多种高级职务。自2008年至2010年,他在宝洁公司(The Procter & Gamble Company)担任了副总裁和全球投资关系方面的总经理。在担任该职位之前,他在瑞典日内瓦担任西欧织物处理部门的财务董事。
Mark J. Erceg joined the Company in February 2021 as Executive Vice President and Chief Financial Officer. Mr. Erceg joined Cerner after serving as Chief Financial Officer of Tiffany & Co. "Tiffany", from October 2016 to January 2021. In that position, Mr. Erceg served as the principal financial officer for Tiffany. Prior to joining Tiffany, Mr. Erceg held the role of Executive Vice President and Chief Financial Officer for Canadian Pacific Railway Limited, a transcontinental railway, from 2015 to 2016 and Masonite International Corporation, a global manufacturer of commercial and residential doors, from 2010 to 2015. Previously, Mr. Erceg held finance, market strategy, general management and global investor relations positions at The Procter & Gamble Company during his tenure there from 1992 to 2010.